The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.

@article{Grey2007ThePP,
  title={The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.},
  author={Andrew Grey and Mark J Bolland and Greg D Gamble and Diana J Wattie and Anne M. Horne and J. Scott Davidson and Ian R Reid},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2007},
  volume={92 4},
  pages={1305-10}
}
CONTEXT Thiazolidinediones, which are peroxisome proliferator-activated receptor-gamma agonists, are widely prescribed to patients with disorders characterized by insulin resistance. Preclinical studies suggest that peroxisome proliferator-activated receptor-gamma signaling negatively regulates bone formation and bone density. Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies. OBJECTIVE The objective of the study was to determine… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 168 extracted citations

Similar Papers

Loading similar papers…